Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study

D. van der Heijde, V. Strand, Y. Tanaka, E. Keystone, J. Kremer, CAF. Zerbini, MH. Cardiel, S. Cohen, P. Nash, YW. Song, D. Tegzová, D. Gruben, G. Wallenstein, CA. Connell, R. Fleischmann, ORAL Scan Investigators,

. 2019 ; 71 (6) : 878-891. [pub] 20190424

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20006630

Grant support
Pfizer, Inc. - International

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial was undertaken to evaluate the efficacy, including inhibition of structural progression, and safety of tofacitinib in patients with active RA and an inadequate response to methotrexate (MTX). Month 24 data from the completed study are reported here. METHODS: Patients were randomized 4:4:1:1 to receive tofacitinib 5 mg or 10 mg twice daily, or placebo, switched to tofacitinib 5 mg or 10 mg twice daily, with stable background MTX. Patients receiving placebo switched to tofacitinib at month 3 (nonresponders) or month 6 (remaining patients). Clinical efficacy, structural progression, and treatment-emergent adverse events were evaluated. Analyses were performed on the full analysis set with observed data or nonresponder imputation with no advancement penalty for clinical efficacy, and imputation by linear extrapolation for structural progression. RESULTS: Overall, 797 patients were treated; 539 (67.6%) completed 24 months of treatment. Responses according to the American College of Rheumatology criteria for 20% improvement (ACR20), ACR50, and ACR70; the proportion of patients in whom remission or low disease activity was achieved according to the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate, Clinical Disease Activity Index, or Simplified Disease Activity Index; Boolean remission; and Health Assessment Questionnaire disability index scores were maintained from month 12 to 24 and were similar between tofacitinib dosages. Limited structural damage was observed at months 12 and 24. Safety events were similar in type and frequency for both tofacitinib dosages, and were consistent with those previously reported. CONCLUSION: Our findings indicate that clinical and radiographic treatment effects are sustained in months 12-24 in patients with RA receiving tofacitinib 5 mg or 10 mg twice daily plus MTX. The safety profile is consistent with that of other tofacitinib studies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006630
003      
CZ-PrNML
005      
20200528110517.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/art.40803 $2 doi
035    __
$a (PubMed)30666826
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a van der Heijde, Désirée $u Leiden University Medical Center, Leiden, The Netherlands.
245    10
$a Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study / $c D. van der Heijde, V. Strand, Y. Tanaka, E. Keystone, J. Kremer, CAF. Zerbini, MH. Cardiel, S. Cohen, P. Nash, YW. Song, D. Tegzová, D. Gruben, G. Wallenstein, CA. Connell, R. Fleischmann, ORAL Scan Investigators,
520    9_
$a OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial was undertaken to evaluate the efficacy, including inhibition of structural progression, and safety of tofacitinib in patients with active RA and an inadequate response to methotrexate (MTX). Month 24 data from the completed study are reported here. METHODS: Patients were randomized 4:4:1:1 to receive tofacitinib 5 mg or 10 mg twice daily, or placebo, switched to tofacitinib 5 mg or 10 mg twice daily, with stable background MTX. Patients receiving placebo switched to tofacitinib at month 3 (nonresponders) or month 6 (remaining patients). Clinical efficacy, structural progression, and treatment-emergent adverse events were evaluated. Analyses were performed on the full analysis set with observed data or nonresponder imputation with no advancement penalty for clinical efficacy, and imputation by linear extrapolation for structural progression. RESULTS: Overall, 797 patients were treated; 539 (67.6%) completed 24 months of treatment. Responses according to the American College of Rheumatology criteria for 20% improvement (ACR20), ACR50, and ACR70; the proportion of patients in whom remission or low disease activity was achieved according to the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate, Clinical Disease Activity Index, or Simplified Disease Activity Index; Boolean remission; and Health Assessment Questionnaire disability index scores were maintained from month 12 to 24 and were similar between tofacitinib dosages. Limited structural damage was observed at months 12 and 24. Safety events were similar in type and frequency for both tofacitinib dosages, and were consistent with those previously reported. CONCLUSION: Our findings indicate that clinical and radiographic treatment effects are sustained in months 12-24 in patients with RA receiving tofacitinib 5 mg or 10 mg twice daily plus MTX. The safety profile is consistent with that of other tofacitinib studies.
650    _2
$a dospělí $7 D000328
650    _2
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a revmatoidní artritida $x diagnostické zobrazování $x farmakoterapie $x patofyziologie $7 D001172
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory Janus kinas $x terapeutické užití $7 D000075242
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x terapeutické užití $7 D008727
650    _2
$a lidé středního věku $7 D008875
650    _2
$a piperidiny $x terapeutické užití $7 D010880
650    _2
$a pyrimidiny $x terapeutické užití $7 D011743
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Strand, Vibeke $u Biopharmaceutical Consultant, Portola Valley, California.
700    1_
$a Tanaka, Yoshiya $u University of Occupational and Environmental Health, Kitakyushu, Japan.
700    1_
$a Keystone, Edward $u Mount Sinai Hospital, Toronto, Ontario, Canada.
700    1_
$a Kremer, Joel $u Albany Medical College, Albany, New York.
700    1_
$a Zerbini, Cristiano A F $u Centro Paulista de Investigação Clinica, Sao Paulo, Brazil.
700    1_
$a Cardiel, Mario H $u Centro de Investigacion Clinica de Morelia, Morelia, Mexico.
700    1_
$a Cohen, Stanley $u Metroplex Clinical Research Center, Dallas, Texas.
700    1_
$a Nash, Peter $u Nambour General Hospital, Nambour, Queensland, Australia, and University of Queensland, Brisbane, Queensland, Australia.
700    1_
$a Song, Yeong-Wook $u Seoul National University Hospital, Seoul, Republic of Korea.
700    1_
$a Tegzová, Dana $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Gruben, David $u Pfizer, Inc., Groton, Connecticut.
700    1_
$a Wallenstein, Gene $u Pfizer, Inc., Groton, Connecticut.
700    1_
$a Connell, Carol A $u Pfizer, Inc., Groton, Connecticut.
700    1_
$a Fleischmann, Roy $u Metroplex Clinical Research Center, Dallas, Texas.
710    2_
$a ORAL Scan Investigators
773    0_
$w MED00188151 $t Arthritis & rheumatology (Hoboken, N.J.) $x 2326-5205 $g Roč. 71, č. 6 (2019), s. 878-891
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30666826 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200528110514 $b ABA008
999    __
$a ok $b bmc $g 1525488 $s 1096686
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 71 $c 6 $d 878-891 $e 20190424 $i 2326-5205 $m Arthritis & rheumatology $n Arthritis Rheumatol $x MED00188151
GRA    __
$p Pfizer, Inc. $2 International
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options